BRIEF-Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases
BRIEF-Selecta Biosciences And Ginkgo Bioworks Holdings Inc Announce Partnership To Advance Treatments For Orphan And Rare Diseases
Oct 26 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
路透10月26日電-銀杏生物工程控股公司(Ginkgo Bioworks Holdings Inc DNA.N)：
* SELECTA BIOSCIENCES AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ADVANCE TREATMENTS FOR ORPHAN AND RARE DISEASES
*Selecta Biosciences和Ginkgo Bioworks宣佈建立合作伙伴關係，推進孤兒和罕見疾病的治療
* SELECTA BIOSCIENCES - LEVERAGING GINKGO'S CELL PROGRAMMING PLATFORM & CO'S IMMTOR PLATFORM TO CREATE POTENTIALLY TRANSFORMATIVE ENZYMATIC THERAPIES
*Selecta Biosciences-利用銀杏的細胞編程平台和CO的IMMTOR平台創建潛在的變革性酶療法
* SELECTA BIOSCIENCES - GAINS RIGHTS TO DEVELOP, COMMERCIALIZE SELECT THERAPEUTIC ENZYMES FROM GINKGO'S ADVANCED ORGANISM ENGINEERING PLATFORM
*Selecta Biosciences-獲得開發銀杏先進生物工程平台的精選治療酶的權利，並將其商業化
* SELECTA BIOSCIENCES - GINKGO IS ELIGIBLE TO EARN CLINICAL AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $85M IN CASH
*Selecta Biosciences-銀杏有資格獲得高達8500萬美元現金的臨牀和商業里程碑付款
* SELECTA BIOSCIENCES - GINKGO ELIGIBLE TO EARN UPFRONT RESEARCH & DEVELOPMENT FEES, MILESTONES, INCLUDING CERTAIN PAYMENTS IN FORM OF CO'S COMMON STOCK
*Selecta Biosciences-銀杏有資格賺取預付研發費用、里程碑，包括以CO普通股形式支付的某些款項
Source text for Eikon: ID:nGNX7rtyW1 Further company coverage: DNA.N
Eikon的源文本：ID：nGNX7rtyW1進一步的公司報道：DNA.N